Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro

Clinical Cancer Research

Volumn 6, Issue 1, 2000, Pages 237-249

  Svingen, Phyllis A ^a   Tefferi, Ayalew ^a   Kottke, Timothy J ^a   Kaur, Gurmeet ^b   Narayanan, Ven L ^b   Sausville, Edward A ^b   Kaufmann, Scott H ^a,c  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ADAPHOSTIN; AG 957; BCR ABL PROTEIN; BLOCKING ANTIBODY; CASPASE 3; CASPASE 9; CYTOCHROME C OXIDASE; FAS ANTIGEN; LONAFARNIB; NSC 654705; NSC 676448; PHOSPHOTRANSFERASE INHIBITOR; TYRPHOSTIN; UNCLASSIFIED DRUG; WORTMANNIN;

ARTICLE; BLAST CELL CRISIS; CHRONIC MYELOID LEUKEMIA; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME RELEASE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; STEM CELL;

ADAMANTANE; APOPTOSIS; CASPASE 9; CASPASES; CELL DIVISION; ENZYME INHIBITORS; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROQUINONES; K562 CELLS; KINETICS; LEUKEMIA, MYELOID, CHRONIC; PROTEIN-TYROSINE KINASES; RECOMBINANT FUSION PROTEINS; TRANSFECTION; TUMOR STEM CELL ASSAY; TYRPHOSTINS;

EID: 0033973544     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (91)

1. Gishizky, M. L., Johnson-White, J., and Witte, O. N. Evaluating the effect of P210 BCR/ABL on growth of hematopoietic progenitor cells and its role in the pathogenesis of human chronic myelogenous leukemia. Semin. Hematol., 30: 6-8, 1993.
2. Faderl, S., Kantaijian, H. M., and Talpaz, M. Chronic myelogenous leukemia. Update on biology and treatment. Oncology, 13: 169-180, 1999.
3. Sawyers, C. L. Chronic myeloid leukemia. N. Engl. J. Med., 340: 1330-1340, 1999.
4. bcr/abl gene of the Philadelphia chromosome. Science (Washington DC), 247: 824-830, 1990.
5. Elfanty, A. G., Hariharan, I. K., and Cory, S. Bcr-abl, the hallmark of chronic myeloid leukaemia in man, induced multiple haemopoietic neoplasms in mice. EMBO J., 9: 1069-1078, 1990.
6. Kelliher, M. A., McLaughlin, J., Witte, O. N., and Rosenberg, N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc. Natl. Acad. Sci. USA, 87: 6649-6653, 1990.
7. Pear, W. S., Miller, J. P., Zu, L., Pui, J. C., Soffer, B., Quackenbush, R. C., Pendergast, A. M., Bronson, R., Aster, J. C., Scott, M. L., and Baltimore, D. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/ abl-transduced bone marrow. Blood, 92: 3780-3792, 1998.
8. Van Etten, R. A., Jackson, P., and Baltimore, D. The mouse Type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell, 58: 669-678, 1989.
9. Dhut, S., Chaplin, T., and Young, B. D. BCR-ABL and BCR proteins. Biochemical characterization and localization. Leukemia (Baltimore), 4: 745-750, 1990.
10. Lugo, T. G., Pendergast, A. M., Muller, A. J., and Witte, O. N. Tyrosine kinase activity and transformation potency of Bcr-Abl oncogene products. Science (Washington DC), 247: 1079-1082, 1990.
11. Sattler, M., and Salgia, R. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. Cytokine Growth Factor Reviews, 8: 63-79, 1997.
12. Gotoh, A., and Broxmeyer, H. E. The function of BCR/ABL and related proto-oncogenes. Curr. Opin. Hematol., 4: 3-11, 1997.
13. Cortez, D., Reuther, G., and Pendergast, A. M. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates Gl-to-S phase transition in hematopoietic cells, Oncogene, 15: 2333-2342, 1997.
14. Laneuville, P., Timm, M., and Hudson, A. T. BCR/ABL expression in 32D c13 (G) cells inhibits apoptosis induced by protein tyrosine kinase inhibitors. Cancer Res., 54: 1360-1366, 1994.
15. McGahon, A., Bissonnette, R., Schmitt, M., Cotter, K. M., Green, D. R., and Cotter, T. G. Bcr-Abl maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood, 83: 1179-1187, 1994.
16. Bedi, A., Zehnbauer, B. A., Barber, J. P., Sharkis, S. J., and Jones, R. J. Inhibition of apoptosis by Bcr-Abl in chronic myeloid leukemia. Blood, 83: 2038-2044, 1994.
17. Dubrez, L., Goldwasser, F., Genne, P., Pommier, Y., and Solary, E. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia (Baltimore), 9: 1013-1024, 1995.
18. s induced differentiation and sensitizes chronic myelogenous leukemia-blast crisis K562 cells to 1-β-D-arabinofuranosylcytosine-mediated differentiation and apoptosis. Cell Growth Differ., 7: 1617-1623, 1996.
19. Cortez, D., Stoica, G., Pierce, J. H., and Pendergast, A. M. The BCR-ABL tyrosine kinase inhibits apoptosis by activating a ras-dependent signaling pathway. Oncogene, 13: 2589-2594, 1996.
20. Martins, L. M., Mesner, P. W., Kottke, T. J., Basi, G. S., Sinha, S., Tung, J. S., Svingen, P. A., Madden, B. J., Takahashi, A., McCormick, D. J., Earnshaw, W. C., and Kaufmann, S. H. Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis. Blood, 90: 4283-4296, 1997.
21. Amarante-Mendes, G. P., Kim, C. N., Liu, L., Huang, Y., Perkins, C., Green, D. R., and Bhalla, K. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood, 91: 1700-1705, 1998.
22. Dubrez, L., Eymin. B., Sordet, O., Droin, N., Turhan, A. G., and Solary, E. Bcr-Abl delays apoptosis upstream of procaspase-3 activation. Blood, 91: 2415-2422, 1998.
23. Cortez, D., Kadlec, L., and Pendergast, A. M. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol. Cell. Biol., 15: 5531-5541, 1995.
24. Gishizky, M. L., Cortez, D., and Pendergast, A. M. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation. Proc. Natl. Acad. Sci. USA, 92: 10889-10893, 1995.
25. Skorski, T., Kanakaraj, P., Nieborowska-Skorska, M., Ratajczak, M. Z., Wen, S. C., Zon, G., Gerwirtz, A. M., Perussia, B., and Calabretta, B. Phosphatidylinositol 3-kinase activity is regulated by Bcr/Abl and is required for the growth of Philadelphia chromosome-positive cells. Blood, 86: 726-736, 1995.
26. Sausville, E. A. A Bcr/Abl kinase antagonist for chronic myelogenous leukemia. A promising path for progress emerges. J. Natl. Cancer Inst., 91: 102-103, 1999.
27. Okabe, M., Uehara, Y., Miyagishima, T., Itaya, T., Tanaka, M., Kuni Eda, Y., Kurosawa, M., and Miyazaki, T. Effect of herbimycin A. an antagonist of tyrosine kinase, on Bcr/Abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing onco-protein P210Bcr/Abl and preferential inhibition on Phi-positive leukemia cell growth. Blood, 80: 1330-1338, 1992.
28. Carlo-Stella, C., Dotti, G., Mangoni, E., Regazzi, E., Garau, D., Bonati, A., Almici, C., Sammarelli, G., Savoldo, B., Rizzo, M. T., and Rizzoli, V. Selection of myeloid progenitors lacking Bcr/Abl mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein. Blood, 88: 3091-3100, 1996.
29. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., and Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med., 2: 561-566, 1996.
30. Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B. J., and Lydon, N. B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res., 56: 100-104, 1996.
31. Deininger, M. W., Goldman, J. M., Lydon, N., and Melo, J. V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of Bcr-Abl-positive cells. Blood, 90: 3691-3698, 1997.
32. Druker, B. J., Sawyers, C. L., Talpaz, M., Resta, D., Peng, B., and Ford, J. Phase I trial of a specific Abl tyrosine inhibitor, CGP 57148, in interferon refractory chronic myelogenous leukemia patients. Blood, 92: 252a, 1998.
33. Levitzki, A., and Gazit, A. Tyrosine kinase inhibition. An approach to drug development. Science (Washington DC), 267: 1782-1788, 1995.
34. Kaur, G., Gazit, A., Levitzki, A., Stowe, E., Cooney, D. A., and Sausville, E. A. Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia. Anti-Cancer Drugs, 5: 213-222, 1994.
35. Drexler, H. G., MacLeod, R. A., and Uphoff, C. C. Leukemia cell lines. In vitro models for the study of Philadelphia chromosome-positive leukemia. Leuk. Res., 23: 207-215, 1999.
36. Kaur, G., and Sausville, E. A. Altered physical state of p21 Obcr/abl in tyrphostin AG957-treated K562 cells. Anti-Cancer Drugs, 7: 815-824, 1996.
37. Jamieson, L., Carpenter, L., Biden, T. J., and Fields, A. P. Protein kinase C iota activity is necessary for Bcr-Abl-mediated resistance to drug-induced apoptosis. J. Biol. Chem., 274: 3927-3930, 1999.
38. Bhatia, R., Munthe, H. A., and Verfaillie, C. M. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores β1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors. Leukemia (Baltimore), 12: 1708-1717, 1998.
39. Smetsers, T. F., Skorski, T., van de Locht, L. T., Wessels, H. M., Pennings, A. H., de Witte, T., Calabretta, B., and Mensink, E. J. Antisense Bcr-Abl oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173. Leukemia (Baltimore), 8: 129-140, 1994.
40. + leukemic cells and induces apoptosis. Blood Cells Mol. Dis., 23: 380-394, 1997.
41. Dan. S., Naito, M., and Tsuruo, T. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase. CGP 57148. Cell Death Differ., 5: 710-715, 1998.
42. cbl phosphorylation in and CD-3-stimulated T-lymphoblasts. Biochem. Pharmacol., 57: 281-289, 1999.
43. Andoniou, C. E., Thien, C. B., and Langdon, W. Y. Tumour induction by activated Abl involves tyrosine phosphorylation of the product of the Cbl oncogene. EMBO J., 13: 4515-4523, 1994.
44. Sattler, M., Salgia, R., Okuda, K., Uemura, N., Durstin, M. A., Pisick, E., Xu, G., Li, J. L., Prasad, K. V., and Griffin, J. D. The proto-oncogene produce p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol 3-kinase pathway. Oncogene, 12: 839-846, 1996.
45. Kaufmann, S. H., Svingen, P. A., Kottke, T. J., Sausville, E. A., and Tefferi. A. Evaluation of the effect of AG957 (NSC 654705) on chronic myelogenous leukemia cells in vitro. Blood, 92 (Suppl. I): 627A, 1998.
46. Mesner, P. W., Jr., Bible, K. C., Martins, L. M., Kottke, T. J., Srinivasula, S. M., Svingen, P. A., Chilcote, T. J., Basi, G. S., Tung, J. S., Karjewski, S., Reed, J. C., Alnemri, E. S., Earnshaw, E. C., and Kaufmann, S. H. Characterization of caspase processing and activation of HL-60 cell cytosol under cell-free conditions: nucleotide requirement and inhibitor profile. J. Biol. Chem., 274: 22635-22645, 1999.
47. Pike, B. L., and Robinson, W. A. Human bone marrow colony growth in agar-gel. J. Cell. Physiol., 76: 77-84, 1970.
48. Kaufmann, S. H., McLaughlin, S. J., Kastan, M., Liu, L. F., Karp, J. E., and Burke, P. J. Topoisomerase II levels during granulocytic maturation in vitro and in vivo. Cancer Res., 51: 3534-3543, 1991.
49. Kottke, T. J., Blajeski, A. L., Martins, L. M., Mesner, P. W., Jr., Davidson, N. E., Earnshaw, W. C., Armstrong, D. K., and Kaufmann, S. H. Comparison of paclitaxel-, 5-fluoro-2′-deoxyuridine- and epidermal growth factor-induced apoptosis: evidence for EGF-induced anoikis. J. Biol. Chem., 274: 15927-15936, 1999.
50. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. Measurement of protein using bicinchoninic acid. Anal. Biochem., 150: 76-85, 1985.
51. Srinivasula, S. M., Ahmad, M., Fernandes-Alnemri, T., and Alnemri, E. S. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol. Cell, 1: 949-957, 1998.
52. Wajant, H., Johannes, F. J., Haas, E., Siemienski, K., Schwenzer, R., Schubert, G., Weiss, T., Grell. M., and Scheurich, P. Dominant-negative FADD inhibits TNFR60-, Fas/Apol-, and TRAIL-R/Apo2-mediated cell death but not gene induction. Curr. Biol., 8: 113-116, 1998.
53. Kaufmann, S. H., Karp, J. E., Jones, R. J., Miller, C. B., Schneider, E., Zwelling, L. A., Cowan, K., Wendel, K., and Burke, P. J. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood, 83: 517-530, 1994.
54. Zar, J. H. Biostatistical Analysis. Englewood Cliffs, NJ: Prentice-Hall, Inc., 1974.
55. Van Etten, R. A., Jackson, P. K., Baltimore, D., Sanders, M. C., Matsudaira, P. T., and Janmey, P. A. The COOH terminus of c-Abl tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity. J. Cell Biol., 124: 325-340, 1994.
56. Okuda, K., Golub, T. R., Gilliland, D. G., and Griffin, J. D. p210BCR/ABL, p190BCR/ABL. and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene, 13: 1147-1152, 1996.
57. Kaufmann, S. H., Desnoyers, S., Ottaviano, Y., Davidson, N. E., and Poirier, G. G. Specific proteolytic fragmentation of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res., 53: 3976-3985, 1993.
58. Earnshaw, W. C., Martins, L. M., and Kaufmann, S. H. Mammalian caspases. Structure, activation, substrates, and functions during apoptosis. Annu. Rev. Biochem., 68: 383-424, 1999.
59. Green, D. R., and Reed, J. C. Mitochondria and apoptosis. Science (Washington DC), 281: 1309-1312, 1998.
60. Perkins, C., Kim, C. N., Fang, G., and Bhalla, K. N. Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells. Cancer Res., 58: 4561-4566, 1998.
61. Sun, X. M., MacFarlane, M., Zhuang, J., Wolf, B. B., Green, D. R., and Cohen, G. M. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J. Biol. Chem., 274: 5053-5060, 1999.
62. Friesen, C., Herr, I., Krammer, P. H., and Debatin, K-M. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med., 2: 574-577, 1996.
63. Muller, M., Strand, S., Hug, H., Heinemann, E. M., Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H., and Galle, P. R. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Investig., 99: 403-413, 1997.
64. Fulda, S., Sieverts, H., Friesen, C., Herr, I., and Debatin, K. M. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res., 57: 3823-3829, 1997.
65. Fulda, S., Los, M., Friesen, C., and Debatin, K. M. Chemosensilivity of solid tumor cells in vitro is related to activation of the CD95 system. Int. J. Cancer, 76: 105-114, 1998.
66. Tillman, D. M., Petak, I., and Houghton, J. A. A fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells. Clin. Cancer Res., 5: 425-430, 1999.
67. Nagata, S. Apoptosis by death factor. Cell, 88: 355-365, 1997.
68. Ashkenazi, A., and Dixit, V. M. Death receptors: signaling and modulation. Science (Washington DC). 281: 1305-1308, 1998.
69. Varfolomeev, E. E., Schuchmann, M., Luria, V., Chiannilkulchai, N., Beckmann, J. S., Mett, I. L., Rebrikov, D., Brodianski, V. M., Kemper, O. C., Kollet, O., Lapidot, T., Soffer, D., Sobe, T., Avraham, K. B., Goncharov, T., Holtmann, H., Lonai, P., and Wallach, D. Targeted disruption of the mouse caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apol, and DR3 and is lethal prenatally. Immunity, 9: 267-276, 1998.
70. Yeh, W-C., de la Pompa, J. L., McCurrach, M. E., Shu, H-B., Elia, A. J., Shahinian, A., Ng, M., Wakeham, A., Khoo, W., Mitchell, K., El-Deiry, W. S., Lowe, S. W., Goeddel, D. V., and Mak, T. W. FADD. Essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science (Washington DC), 279: 1954-1958, 1998.
71. Yonehara, S., Nishimura, Y., Kishil, S., Yonehara, M., Takazawa, K., Tamatani, T., and Ishii, A. Involvement of apoptosis antigen fas in clonal deletion of human thymocytes. Int. Immunol., 6: 1849-1856, 1994.
72. Eischen, C. M., Kottke, T. J., Martins, L. M., Basi, G. S., Tung, J. S., Earnshaw, W. C., Leibson, P. J., and Kaufmann, S. H. Comparison of apoptosis in wild-type and fas-resistant cells: chemotherapy-induced apoptosis is not dependent on fas/fas ligand interactions. Blood, 90: 935-943, 1997.
73. Houghton, J. A., Harwood, F. G., Gibson, A. A., and Tillman, D. M. The fas signaling pathway is functional in colon carcinoma cells and induces apoptosis. Clin. Cancer Res., 3: 2205-2209, 1997.
74. Chaudhary, P. M., Eby, M., Jasmin, A., Bookwalter, A., Murray, J., and Hood, L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity, 7: 821-830, 1997.
75. Liu, M., Bryant, M. S., Chen, J., Lee, S., Yaremko, B., Lipari, P., Malkowski, M., Ferrari, E., Nielsen, L., Prioli, N., Dell, J., Sinha, D., Syed, J., Korfmacher, W. A., Nomeir, A. A., Lin, C. C., Wang, L., Taveras, A. G., Doll, R. J., Njoroge, F. G., Mallams, A. K., Remis-zewski, S., Catino, J. J., Girijavallabhan, V. M., and Bishop, W. R. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res., 58: 4947-4956, 1998.
76. Yano, H., Nakanishi, S., Kimura, K., Hanai, N., Saitoh, Y., Fukui, Y., Nonomura, Y., and Matsuda, Y. Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells. J. Biol. Chem., 268: 25846-25856, 1993.
77. Powis, G., Bonjoulkian, R., Berggren, M. M., Gallegos, A., Abraham, R., Ashendel, C., Zalkow, L., Matter, W. F., Dodge, J., and Grindey, G. Wortmannin, a potent and selective inhibitor of phosphatidylinositol3-kinase. Cancer Res., 54: 2419-2423, 1994.
78. Pang, L., Sawada, T., Decker, S. J., and Saltiel, A. R. Inhibition of MAP kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J. Biol. Chem., 270: 13585-13588, 1995.
79. Chang, M. P., Bramhall, J., Graves, S., Bonavida, B., and Wisnieski, B. J. Internucleosomal DNA cleavage precedes diphtheria toxin-induced cytolysis. Evidence that cell lysis is not a simple consequence of translation inhibition. J. Biol. Chem., 264: 15261-15267, 1989.
80. Budihardjo, I. I., Walker, D. L., Svingen, P. A., Buckwalter, C. A., Desnoyers. S., Eckdahl, S., Shah, G. M., Poirier, G. G., Reid. J. M., Ames, M. M., and Kaufmann, S. H. 6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin. Clin. Cancer Res., 4: 117-130, 1998.
81. Hollingshead, M. G., Alley, M. C., Camalier, R. F., Abbott, B. .1., Mayo, J. G., Malspeis, L., and Grever. A. L. In vitro cultivation of tumor cells in hollow fibers. Life Sci., 57: 131-141, 1995.
82. + chronic myelogenous leukemia progenitor cells. Blood, 93: 3973-3982, 1999.
83. Kantarjian, H. M., O'Brien, S., Anderlini, P., and Talpaz, M. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood, 87: 3069-3081, 1996.
84. Enright, H., and McGlave, P. B. Biology and treatment of chronic myelogenous leukemia. Oncology, 11: 295-1300, 1997.
85. Bhatia, R., Verfaillie, C. M., Miller, J. S., and McGlave, P. H. Autologous transplantation therapy for chronic myelogenous leukemia. Blood, 89: 2623-2634, 1997.
86. Deisseroth, A. B., Zu, Z., Claxton, D., Hanania, E. G., Fu, S., Ellerson, D., Goldberg, L., Thomas, M., Janicek, K., Anderson, W. F., Hester, J., Korbling, M., Durett, A., Moen, R., Berenson, R., Heimfeld, S., Hamer, J., Calvert, L., Tibbits, P., Talpaz, M., Kantarjian, H., Champlin, R., and Reading, C. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood, 83: 3068-3076, 1994.
87. Verfaillie, C. M., Bhatia, R., Steinbuch, M., DeFor, T., Hirsch, B., Miller, J. S., Weisdorf, D., and McGlave, P. B. Comparative analysis of autografting in chronic myelogenous leukemia: effects of priming regimen and marrow or blood origin of stem cells. Blood, 92: 1820-1831, 1998.
88. Samajima, K., Tone, S., Kottke, T. J., Enari, M., Sakahira, H., Cooke, C. A., Durrein, F., Martins, L. M., Nagata, S., Kaufmann, S. H., and Earnshaw, W. F. Transition from caspase-dependent to caspase-independent mechanisms at the onset of apoptotic execution. J. Cell Biol., 143: 225-239, 1998.
89. Sarkaria, J. N., Tibbetts, R. S., Busby, E. C., Kennedy, A. P., Hill, D. E., and Abraham, R. T. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res., 58: 4375-4382, 1998.
90. Sutor, S. L., Vroman, B. T., Armstrong, E. A., Abraham, R. T., and Karnitz, L. M. A phosphatidylinositol 3-kinase-dependent pathway that differentially regulates c-raf and a-raf. J. Biol. Chem., 274: 7002-7010, 1999.
91. Eaves, C., Udomsakdi, C., Cashman, J., Barnett, M., and Eaves, A. The biology of normal and neoplastic stem cells in CML. Leuk. Lymphoma, 11: 245-253, 1993.